Jie Tang1, Hui Zhao2, Haikang Cai1, Haishan Wu3. 1. Department of Orthopaedics, Xuhui Central Hospital, Shanghai, 200031, China. 2. Department of Joint Center, Changzheng Hospital, the Second Military Medical University, No. 440, North Chengdu Road, Shanghai, 200003, China. 3. Department of Joint Center, Changzheng Hospital, the Second Military Medical University, No. 440, North Chengdu Road, Shanghai, 200003, China. Electronic address: haishan_wu@126.com.
Abstract
AIM: Growing evidence suggest that the microRNA (miR)-23a/24-2/27a cluster may play a crucial role in mammary tumorigenesis and act as a novel class of oncogenes. Among these members, miR-27a has been reported to promote proliferation, migration and invasion in human osteosarcoma cells. The aim of this study was to detect the serum levels of miR-27a in osteosarcoma patients and to investigate its associations with clinicopathological features and prognosis. METHODS: miR-27a levels in sera from 166 osteosarcoma patients and 60 healthy controls were detected by real-time quantitative RT-PCR. Then, the associations of serum miR-27a level with clinicopathological factors or survival of osteosarcoma patients were further evaluated. RESULTS: Compared to healthy controls, the serum levels of miR-27a were significantly increased in osteosarcoma patients (P<0.001). Importantly, miR-27a could efficiently screen osteosarcoma patients from healthy controls (Area under receiver operating characteristic curve, AUC=0.867). Then, high miR-27a expression was more frequently occurred in osteosarcoma patients with advanced clinical stage (P=0.001), positive distant metastasis (P=0.01) and poor response to chemotherapy (P=0.008). In Kaplan-Meier survival analysis, high miR-27a expression was a significant indicator for poor overall survival (P=0.006) as well as poor disease-free survival (P=0.01). Furthermore, multivariate analysis demonstrated that miR-27a expression was an independent and significant prognostic factor to predict overall survival (P=0.01) and disease-free survival (P=0.03). CONCLUSION: miR-27a expression may be elevated in sera of osteosarcoma patients and in turn contributes to aggressive progression of this malignancy. Detection of serum miR-27a levels may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
AIM: Growing evidence suggest that the microRNA (miR)-23a/24-2/27a cluster may play a crucial role in mammary tumorigenesis and act as a novel class of oncogenes. Among these members, miR-27a has been reported to promote proliferation, migration and invasion in humanosteosarcoma cells. The aim of this study was to detect the serum levels of miR-27a in osteosarcomapatients and to investigate its associations with clinicopathological features and prognosis. METHODS:miR-27a levels in sera from 166 osteosarcomapatients and 60 healthy controls were detected by real-time quantitative RT-PCR. Then, the associations of serum miR-27a level with clinicopathological factors or survival of osteosarcomapatients were further evaluated. RESULTS: Compared to healthy controls, the serum levels of miR-27a were significantly increased in osteosarcomapatients (P<0.001). Importantly, miR-27a could efficiently screen osteosarcomapatients from healthy controls (Area under receiver operating characteristic curve, AUC=0.867). Then, high miR-27a expression was more frequently occurred in osteosarcomapatients with advanced clinical stage (P=0.001), positive distant metastasis (P=0.01) and poor response to chemotherapy (P=0.008). In Kaplan-Meier survival analysis, high miR-27a expression was a significant indicator for poor overall survival (P=0.006) as well as poor disease-free survival (P=0.01). Furthermore, multivariate analysis demonstrated that miR-27a expression was an independent and significant prognostic factor to predict overall survival (P=0.01) and disease-free survival (P=0.03). CONCLUSION:miR-27a expression may be elevated in sera of osteosarcomapatients and in turn contributes to aggressive progression of this malignancy. Detection of serum miR-27a levels may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcomapatients.